Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment

Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Phase I Study of Magnetic Resonance Guided High Intensity Focused Ultrasound for Treatment of Advanced Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04298242
• Other study ID #: IRB-52567
• Secondary ID: PANC0034NCI-2020
• Status: Completed
• Phase: N/A
• Start date: November 22, 2020
• Est. completion date: June 15, 2021

Study information

• Verified date: November 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of advanced stage pancreatic adenocarcinoma.

Description:

Primary Objective: The primary endpoints for this study will be 1) feasibility of ablation and 2) safety of ablation.

Secondary Objective: 1.)Pain reduction after ablation. 2.) Evidence of inflammation at ablation site based on histology, or in blood after ablation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: June 15, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women = 18 years of age

• Patients willing to sign a written informed consent document

• Patients with unresectable, locally advanced or metastatic pancreatic adenocarcinoma

• Patients with upper abdominal pain rating at least 4 out of 10 in severity on BPI

• Tumor must be visualized on CT or MRI, obtained within 30 days of enrollment

• Tumor must be accessible to the ExAblate MRgFUS device

• Life expectancy = 3 months, as determined by oncologist and documented in chart

• ECOG performance status of 0, 1, or 2

• INR < 1.6, platelet count > 50,000 microL

• Serum urate, calcium, potassium, phosphate, creatinine < 1.5x upper limit of normal

• Patients can receive general anesthesia, as determined by anesthesiologist

Exclusion Criteria:

• Previous pancreatic surgery

• Patients with contraindication for MR imaging such as implanted metallic devices that are not MRI-safe, size limitations, claustrophobia, etc.

• Patients with known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease (GFR <30 mL/min/1.73 m2) or on dialysis

• Pregnant and nursing patients will be excluded from the study because of a contraindication to administering MRI contrast agents to these patients

• Patients unable to receive general anesthesia

• Target is:

1. NOT visible by non-contrast MRI, OR

2. NOT accessible to ExAblate device

• Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 6 hrs of total table time)

• Patients with acute medical condition (e.g. pneumonia, sepsis) that is expected to hinder them from completing this study

• Patients with unstable cardiac status including:

1. Unstable angina pectoris on medication

2. Patients with documented myocardial infarction within six months of protocol entry

3. Congestive heart failure requiring medication (other than diuretic)

4. Patients on anti-arrhythmic drugs

5. Patients with severe hypertension (diastolic BP > 100 on medication)

6. Patients with severe hematologic, neurologic, or other uncontrolled disease (e.g. platelets < 50,000/microL, INR > 1.5)

• Patients who are taking anti-thrombotic medication

• Severe cerebrovascular disease (multiple CVAs or CVA within 6 months)

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma

Intervention

Device:
• ExAblate 2100
A non-invasive thermal ablation device fully integrated with an MR imaging system

Locations

Country	Name	City	State
United States	Stanford Cancer Center	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure acceptable ablation percentage	Feasibility of ablation, as measured by the number of patients with acceptable ablation percentage. Acceptable ablation percentage is defined as =50% of the targeted volume appearing ablated on post-treatment imaging. Ablation will be deemed feasible if at least seven of the ten patients have an acceptable ablation percentage	Immediately after MRgFUS treatment
Primary	Total frequency and severity of adverse events	Safety of ablation, as measured by the total frequency and severity of adverse events. Adverse events will be categorized and grade for severity according to the Common Terminology Criteria for Adverse Events, Version 5.0. Ablation will be deemed safe if there are no treatment-related serious adverse events, and no more than five moderate or mild treatment-related adverse events, among the ten patients during follow up.	24 months
Secondary	Assess Pain Response assessed by the Brief Pain Inventory (BPI)	Reduction in pain level, as measured by: a. a decline in pain score after one week of at least 2 points, or a pain score < 4 out of 10, as assessed by the Brief Pain Inventory. Ablation will be deemed pain reducing if at least five of the ten patients have pain reduction.	Baseline, 1 week, and monthly for 24 months following treatment
Secondary	Assess Pain Response assessed by morphine equivalent daily dose (MEDD)	Reduction in pain level will be measured by a decline after one week in morphine equivalent daily dose (MEDD) of 25%. Ablation will be deemed pain reducing if at least five of the ten patients have pain reduction.	Baseline, 1 week, and monthly for 24 months following treatment
Secondary	Evidence of ablation-induced inflammation	Evidence of ablation-induced inflammation, defined as post-ablation increases in histologic and/or blood measures of inflammation markers, as measured by either: an increase in tumor infiltrating CD8+ T cells; a decrease in immune suppressive cells (Tregs, macrophages) in the tumor; an increase in immune activation signatures (including interferon gamma) in the tumor as measured by RNAseq; a change in immune profile in the circulating immune cells (PBMCs) to reflect an activated immune response (e.g. activated T or B cells, reduction in immune suppressive cells or cytokines) Ablation will be deemed inflammation-inducing if at least five of the ten patients show at least a 50% increase in inflammation on at least 2 of the 4 markers	1week